<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="CMV infection. The risk factors for viral infections were allo-HCT," exact="acute leukemia," post="acute and chronic graft versus host disease (a/cGVHD), and"/>
 <result pre="factor for death from viral infection were CMV-IgG seropositivity in" exact="acute lymphoblastic leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
 <result pre="for death from viral infection were CMV-IgG seropositivity in acute" exact="lymphoblastic leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
 <result pre="death from viral infection were CMV-IgG seropositivity in acute lymphoblastic" exact="leukemia" post="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring"/>
 <result pre="(allo-HCT)4 and in 21% of children with solid tumor or" exact="lymphoma" post="in pediatric auto-HCT setting.5 The incidence of viral infection"/>
 <result pre="result of a reactivation event.6 In the early post-transplant period" exact="herpes simplex" post="virus (HSV) reactivation was the most frequent viral infection"/>
 <result pre="HSV, VZV, polyoma BK virus (BKV), while episodic viruses included" exact="influenza" post="A and B (FLUAV and FLUBV, respectively) and other"/>
 <result pre="(741 allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were:" exact="acute lymphoblastic leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
 <result pre="allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were: acute" exact="lymphoblastic leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
 <result pre="230 auto-HCT) were performed. Indications for HCTs were: acute lymphoblastic" exact="leukemia" post="(ALL, n=233), acute myeloblastic leukemia (AML, n=151), neuroblastoma (n=138),"/>
 <result pre="for HCTs were: acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic" exact="leukemia" post="(AML, n=151), neuroblastoma (n=138), primary immunodeficiencies (n=113), bone marrow"/>
 <result pre="acute lymphoblastic leukemia (ALL, n=233), acute myeloblastic leukemia (AML, n=151)," exact="neuroblastoma" post="(n=138), primary immunodeficiencies (n=113), bone marrow failure syndromes (n=101),"/>
 <result pre="syndromes (n=101), Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing" exact="sarcoma" post="(n=44), myelodysplastic syndrome (n=38) and other indications (n=88). Incidence"/>
 <result pre="Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, n=65), Ewing sarcoma (n=44)," exact="myelodysplastic syndrome" post="(n=38) and other indications (n=88). Incidence of Infection A"/>
 <result pre="cytomegalovirus; CMV-CTL, cytomegalovirus specific T lymphocytes; EBV, Epstein–Barr virus; FLUAV," exact="influenza" post="A virus; HBV, hepatitis B virus; HHV-6, human herpesvirus"/>
 <result pre="T lymphocytes; EBV, Epstein–Barr virus; FLUAV, influenza A virus; HBV," exact="hepatitis" post="B virus; HHV-6, human herpesvirus 6; hMPV, human metapneumovirus;"/>
 <result pre="than auto-HCT. In allo-HCT patients, the risk was higher in" exact="acute leukemia" post="patients vs other (HR=1.9; p&amp;lt;0.001), MUD vs MSD (HR=2.6;"/>
 <result pre="auto-HCT. In allo-HCT patients, the risk was higher in acute" exact="leukemia" post="patients vs other (HR=1.9; p&amp;lt;0.001), MUD vs MSD (HR=2.6;"/>
 <result pre="&amp;lt;0.001 allo-HCT Sex male vs female 0.9 (0.7–1.1) 0.698 Acute" exact="leukemia" post="vs other 1.9 (1.4–2.4) &amp;lt;0.001 NHL/HD vs other 1.2"/>
 <result pre="bold font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; D, days;"/>
 <result pre="font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; D, days;"/>
 <result pre="(1.1–2.0) 0.045 Sex male vs female 1.1 (0.8–1.5) 0.829 Acute" exact="leukemia" post="vs other 1.5 (0.8–2.4) 0.413 NHL/HD vs other 0.9"/>
 <result pre="bold font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; CMV, cytomegalovirus;"/>
 <result pre="font. Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="ANC, absolute neutrophil count; BM, bone marrow; CMV, cytomegalovirus;"/>
 <result pre="rate of 90.7%. Cesaro et al. reported that BKV-related hemorrhagic" exact="cystitis" post="occurred in 8–25% of pediatric and 7–54% of adult"/>
 <result pre="the lack of significant effects on BKV replication and hemorrhagic" exact="cystitis" post="severity, and the selection of antibiotic resistance.19 In our"/>
 <result pre="clinical manifestations of ADV infections in immunocompetent hosts include upper" exact="respiratory disease," post="gastroenteritis or (kerato-)conjunctivitis and are self-limited in most cases,"/>
 <result pre="of ADV infections in immunocompetent hosts include upper respiratory disease," exact="gastroenteritis" post="or (kerato-)conjunctivitis and are self-limited in most cases, although"/>
 <result pre="in most cases, although severe manifestations including encephalitis, myocarditis, and" exact="pneumonia" post="have been sporadically observed. In immunocompromised patients, ADV can"/>
 <result pre="a significant cause of morbidity and mortality in patients with" exact="leukemia" post="and those undergoing HCT.12,21 In the late 1990s the"/>
 <result pre="and RhV.12 We observed a relatively low (1.2%) rate of" exact="influenza" post="A infection, with no cases of influenza B infection,"/>
 <result pre="(1.2%) rate of influenza A infection, with no cases of" exact="influenza" post="B infection, which may be due to environmental prophylaxis"/>
 <result pre="contacts, and hospital and prophylactic use of neuraminidase inhibitors during" exact="influenza" post="season in some cases). The current guidelines of the"/>
 <result pre="for influenza.23 RV and NoV are important pathogens of viral" exact="gastroenteritis" post="in children. We observed that cumulative incidence of RV"/>
 <result pre="pediatric allo-HCT recipients.24,25 In pediatric HCT, the incidence of NoV-associated" exact="gastroenteritis" post="was reported in 12.9% with no NoV-related mortality.26 PCR"/>
 <result pre="no therapy.8 However, it may be manifested as encephalitis/myelitis, pneumonia," exact="hepatitis" post="and EBV-associated tumors as PTLD.8,29 After transplantation 14–65% of"/>
 <result pre="response rate (50–88%) and fewer relapse.28 We found that allo-HCT," exact="acute leukemia," post="a/cGVHD, MUD/MMUD-HCT were the risk factors for viral infections."/>
 <result pre="viral infection. The risk factors for viral infections were allo-HCT," exact="acute leukemia," post="a/cGVHD, MUD/MMUD vs MSD. The risk factor for death"/>
 <result pre="factor for death from viral infection were CMV-IgG seropositivity in" exact="acute lymphoblastic leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
 <result pre="for death from viral infection were CMV-IgG seropositivity in acute" exact="lymphoblastic leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
 <result pre="death from viral infection were CMV-IgG seropositivity in acute lymphoblastic" exact="leukemia" post="recipients, MUD/MMUD vs MSD. The incidence of EBV infection"/>
 <result pre="aciclovir; ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL," exact="acute lymphoblastic leukemia;" post="allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil"/>
 <result pre="ADV, adenovirus; a/cGVHD, acute/chronic graft versus host disease; ALL, acute" exact="lymphoblastic leukemia;" post="allo-, allogeneic; AML, acute myeloblastic leukemia; ANC, absolute neutrophil"/>
 <result pre="ECIL, European Conference on Infections in Leukaemia; FCV, foscarnet; FLUAV," exact="influenza" post="A virus; FLUBV, influenza B virus; GCV, ganciclovir; HBV,"/>
 <result pre="Infections in Leukaemia; FCV, foscarnet; FLUAV, influenza A virus; FLUBV," exact="influenza" post="B virus; GCV, ganciclovir; HBV, hepatitis B virus; HCT,"/>
 <result pre="influenza A virus; FLUBV, influenza B virus; GCV, ganciclovir; HBV," exact="hepatitis" post="B virus; HCT, hematopoietic cell transplantation; HD, Hodgkin lymphoma;"/>
 <result pre="6; hMPV, human metapneumovirus; HPIV, parainfluenza; HR, hazard ratio; HSV," exact="herpes simplex" post="virus; IQR, quartiles; MAC, myeloablative conditioning; MEL, melphalan; MMUD,"/>
 <result pre="serostatus on the incidence of graft-versus-host disease in patients with" exact="acute leukemia" post="after hematopoietic stem-cell transplantation: a study from the acute"/>
 <result pre="on the incidence of graft-versus-host disease in patients with acute" exact="leukemia" post="after hematopoietic stem-cell transplantation: a study from the acute"/>
 <result pre="acute leukemia after hematopoietic stem-cell transplantation: a study from the" exact="acute leukemia" post="and infectious diseases working parties of the European society"/>
 <result pre="leukemia after hematopoietic stem-cell transplantation: a study from the acute" exact="leukemia" post="and infectious diseases working parties of the European society"/>
 <result pre="for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic" exact="cystitis" post="in haematopoietic stem cell transplant recipients. J Antimicrob Chemother."/>
 <result pre="European guidelines for diagnosis and treatment of adenovirus infection in" exact="leukemia" post="and stem cell transplantation: summary of ECIL-4 (2011). Transpl"/>
 <result pre="CamaraR, CordonnierC, LjungmanP. European guidelines for prevention and management of" exact="influenza" post="in hematopoietic stem cell transplantation and leukemia patients: summary"/>
 <result pre="and management of influenza in hematopoietic stem cell transplantation and" exact="leukemia" post="patients: summary of ECIL-4 (2011), on behalf of ECIL,"/>
 <result pre="Biol Blood Marrow Transplant. 2012;18(12):1883–1889. doi:10.1016/j.bbmt.2012.07.00522796532 27.WilliamsD. Treatment of rotavirus-associated" exact="diarrhea" post="using enteral immunoglobulins for pediatric stem cell transplant patients."/>
</results>
